These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15203915)

  • 1. The use of live attenuated bacteria as a delivery system for heterologous antigens.
    Garmory HS; Leary SE; Griffin KF; Williamson ED; Brown KA; Titball RW
    J Drug Target; 2003; 11(8-10):471-9. PubMed ID: 15203915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuated salmonella and Shigella as carriers for DNA vaccines.
    Xu F; Ulmer JB
    J Drug Target; 2003; 11(8-10):481-8. PubMed ID: 15203916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines.
    Dietrich G; Spreng S; Favre D; Viret JF; Guzman CA
    Curr Opin Mol Ther; 2003 Feb; 5(1):10-9. PubMed ID: 12669465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus.
    Bennett AM; Phillpotts RJ; Perkins SD; Jacobs SC; Williamson ED
    Vaccine; 1999 Nov; 18(7-8):588-96. PubMed ID: 10547416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of attenuated bacteria as delivery vectors for DNA vaccines.
    Daudel D; Weidinger G; Spreng S
    Expert Rev Vaccines; 2007 Feb; 6(1):97-110. PubMed ID: 17280482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yersinia outer protein E, YopE. A versatile type III effector molecule for cytosolic targeting of heterologous antigens by attenuated Salmonella.
    Rüssmann H
    Adv Exp Med Biol; 2003; 529():407-13. PubMed ID: 12756799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.
    Sanapala S; Rahav H; Patel H; Sun W; Curtiss R
    Vaccine; 2016 May; 34(21):2410-2416. PubMed ID: 27060051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A stable plasmid system for heterologous antigen expression in attenuated Vibrio anguillarum.
    Xiao Y; Liu Q; Chen H; Zhang Y
    Vaccine; 2011 Sep; 29(40):6986-93. PubMed ID: 21791231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens.
    Stevenson A; Roberts M
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):121-8. PubMed ID: 12832115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet?
    Lewis GK
    Expert Rev Vaccines; 2007 Jun; 6(3):431-40. PubMed ID: 17542757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes.
    Loeffler DI; Schoen CU; Goebel W; Pilgrim S
    Infect Immun; 2006 Jul; 74(7):3946-57. PubMed ID: 16790768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmid maintenance systems suitable for GMO-based bacterial vaccines.
    Spreng S; Viret JF
    Vaccine; 2005 Mar; 23(17-18):2060-5. PubMed ID: 15755571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against plague afforded by immunisation with DNA vaccines optimised for expression of the Yersinia pestis V antigen.
    Garmory HS; Freeman D; Brown KA; Titball RW
    Vaccine; 2004 Feb; 22(8):947-57. PubMed ID: 15161071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can a 'flawless' live vector vaccine strain be engineered?
    Galen JE; Levine MM
    Trends Microbiol; 2001 Aug; 9(8):372-6. PubMed ID: 11514219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular bacteria as targets and carriers for vaccination.
    Mollenkopf H; Dietrich G; Kaufmann SH
    Biol Chem; 2001 Apr; 382(4):521-32. PubMed ID: 11405217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of a plasmid coding for a heterologous antigen in Salmonella enterica serotype typhi vaccine strain CVD908-htrA by using site-specific recombination.
    Stephens JC; Darsley MJ; Turner AK
    Infect Immun; 2006 Jul; 74(7):4383-6. PubMed ID: 16790817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
    Jia Q; Bowen R; Dillon BJ; Masleša-Galić S; Chang BT; Kaidi AC; Horwitz MA
    Sci Rep; 2018 May; 8(1):7009. PubMed ID: 29725025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits.
    Eyles JE; Williamson ED; Spiers ID; Stagg AJ; Jones SM; Alpar HO
    J Control Release; 2000 Jan; 63(1-2):191-200. PubMed ID: 10640592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.
    Daniel C; Sebbane F; Poiret S; Goudercourt D; Dewulf J; Mullet C; Simonet M; Pot B
    Vaccine; 2009 Feb; 27(8):1141-4. PubMed ID: 19135495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague.
    Garmory HS; Griffin KF; Brown KA; Titball RW
    Vaccine; 2003 Jun; 21(21-22):3051-7. PubMed ID: 12798649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.